CD33 and acute lymphoblastic leukemia: Notably, our findings reveal that the ProB-ALL subtype display significantly elevated expression levels of myeloid markers, including CD66c, CD33 and CD13, concomitant by a tendency toward lower expression of CD9, this profile contrasts to the PreB-ALL cases.